{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T07:12:21Z","timestamp":1787901141599,"version":"build-2784847793"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["UMO-2020\/39\/D\/NZ7\/00789"],"award-info":[{"award-number":["UMO-2020\/39\/D\/NZ7\/00789"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"National Science Centre Poland","doi-asserted-by":"publisher","award":["2020\/04\/X\/NZ5\/00553"],"award-info":[{"award-number":["2020\/04\/X\/NZ5\/00553"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.biopha.2024.116892","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:27:47Z","timestamp":1718238467000},"page":"116892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells"],"prefix":"10.1016","volume":"176","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3606-3623","authenticated-orcid":false,"given":"Malgorzata","family":"Kucinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pospieszna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-7710","authenticated-orcid":false,"given":"Jing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-6594","authenticated-orcid":false,"given":"Natalia","family":"Lisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Toton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1730-0176","authenticated-orcid":false,"given":"Blazej","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Murias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2024.116892_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.33918","article-title":"Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system","volume":"128","author":"Gritsch","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2024.116892_bib2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.32074\/1591-951X-823","article-title":"Adult type diffuse gliomas in the new 2021 WHO Classification","volume":"114","author":"Antonelli","year":"2022","journal-title":"Pathologica"},{"key":"10.1016\/j.biopha.2024.116892_bib3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The Somatic Genomic Landscape of Glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2024.116892_bib4","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/biomedicines10030728","article-title":"Detection of TERT Promoter Mutations as a Prognostic Biomarker in Gliomas: Methodology, Prospects, and Advances","volume":"10","author":"Hasanau","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2024.116892_bib5","first-page":"299","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"Ca. Cancer J. Clin."},{"key":"10.1016\/j.biopha.2024.116892_bib6","first-page":"usad162","article-title":"Association of Traumatic Brain Injury and Glioblastoma Multiforme: A Case Series","author":"An","year":"2023","journal-title":"Mil. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/nop\/npz059","article-title":"Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014","volume":"7","author":"Ostrom","year":"2020","journal-title":"Neuro-Oncol. Pract."},{"key":"10.1016\/j.biopha.2024.116892_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/neuonc\/noac217","article-title":"Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000\u20132014 (CONCORD-3)","volume":"25","author":"Girardi","year":"2023","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib9","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/cancers14133161","article-title":"Survival Outcomes and Prognostic Factors in Glioblastoma","volume":"14","author":"Brown","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116892_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-68011-4","article-title":"Longer-term (\u2265 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis","volume":"10","author":"Poon","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116892_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib12","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/biomedicines9030324","article-title":"Current FDA-approved therapies for high-grade malignant gliomas","volume":"9","author":"Fisher","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2024.116892_bib13","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.5603\/RPOR.a2022.0113","article-title":"Survival and quality of life analysis in glioblastoma multiforme with adjuvant chemoradiotherapy: a retrospective study","volume":"27","author":"Mohammed","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"10.1016\/j.biopha.2024.116892_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112816","article-title":"Coexisting cancer stem cells with heterogeneous gene amplifications, transcriptional profiles, and malignancy are isolated from single glioblastomas","volume":"42","author":"De Bacco","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2024.116892_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130510","article-title":"Asymmetric cell division promotes therapeutic resistance in glioblastoma stem cells","volume":"6","author":"Hitomi","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2024.116892_bib16","doi-asserted-by":"crossref","first-page":"16062","DOI":"10.1073\/pnas.1106704108","article-title":"Metabolic state of glioma stem cells and nontumorigenic cells","volume":"108","author":"Vlashi","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2024.116892_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107985","article-title":"Cell plasticity, senescence, and quiescence in cancer stem cells: Biological and therapeutic implications","volume":"231","author":"Paul","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2024.116892_bib18","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.molcel.2020.05.031","article-title":"Rational Cancer Treatment Combinations: An Urgent Clinical Need","volume":"78","author":"Boshuizen","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2024.116892_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3390\/cancers14030600","article-title":"Advancements, Challenges, and Future Directions in Tackling Glioblastoma Resistance to Small Kinase Inhibitors","volume":"14","author":"Fabro","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116892_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3390\/pharmaceutics15010059","article-title":"Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery","volume":"15","author":"Brar","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2024.116892_bib21","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","article-title":"How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment","volume":"39","author":"Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.biopha.2024.116892_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102087","article-title":"The cancer premium \u2013 explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland: a cross sectional study","volume":"61","author":"Serra-Burriel","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.biopha.2024.116892_bib23","first-page":"1","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","author":"Weth","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2024.116892_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41392-020-0118-x","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2024.116892_bib25","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/cancers13081953","article-title":"An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma","volume":"13","author":"Lyne","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2024.116892_bib26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ebiom.2015.08.026","article-title":"The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes","volume":"2","author":"Xie","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.biopha.2024.116892_bib27","doi-asserted-by":"crossref","first-page":"8200","DOI":"10.1021\/acs.jmedchem.5b01073","article-title":"Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor","volume":"58","author":"Zeng","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2024.116892_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4161\/cbt.28585","article-title":"Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K\/mTOR dual inhibitor PF-05212384","volume":"15","author":"Zhu","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2024.116892_bib29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s00280-021-04242-0","article-title":"Foretinib induces G2\/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition","volume":"87","author":"Gortany","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116892_bib30","doi-asserted-by":"crossref","first-page":"37568","DOI":"10.18632\/oncotarget.17247","article-title":"Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit","volume":"8","author":"Oliva","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116892_bib31","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3858\/emm.2010.42.5.041","article-title":"Chlorpromazine activates p21Waf1\/Cip1 gene transcription via early growth response-1 (Egr-1) in C6 glioma cells","volume":"42","author":"Shin","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib32","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/carcin\/bgt169","article-title":"The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt\/mTOR pathway in human U-87MG glioma cells","volume":"34","author":"Shin","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2024.116892_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121335","article-title":"Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens","volume":"281","author":"Lu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2024.116892_bib34","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bbi.2011.01.015","article-title":"Minocycline reduces glioma expansion and invasion by attenuating microglial MT1-MMP expression","volume":"25","author":"Markovic","year":"2011","journal-title":"Brain. Behav. Immun."},{"key":"10.1016\/j.biopha.2024.116892_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123721","article-title":"Metformin Inhibits Growth of Human Glioblastoma Cells and Enhances Therapeutic Response","volume":"10","author":"Sesen","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.biopha.2024.116892_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2006.04.032","article-title":"Arginine vasopressin stimulates 11beta-hydroxysteroid dehydrogenase type 2 expression in the mineralocorticosteroid target cells","volume":"256","author":"Rubis","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2024.116892_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinforma."},{"key":"10.1016\/j.biopha.2024.116892_bib38","doi-asserted-by":"crossref","first-page":"5278","DOI":"10.3390\/ijms21155278","article-title":"Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting","volume":"21","author":"Vieira de Castro","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116892_bib39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13287-021-02231-x","article-title":"Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives","volume":"12","author":"Alves","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.biopha.2024.116892_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110493","article-title":"Signaling pathways governing glioma cancer stem cells behavior","volume":"101","author":"Nasrolahi","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.biopha.2024.116892_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026740","article-title":"Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas","volume":"6","author":"Alonso","year":"2011","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2024.116892_bib42","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.3892\/ol.2016.5065","article-title":"Expression and significance of SOX2 in non-small cell lung carcinoma","volume":"12","author":"Ying","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2024.116892_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153023","article-title":"The function of SOX2 in breast cancer and relevant signaling pathway","volume":"216","author":"Meng","year":"2020","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.biopha.2024.116892_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.881246","article-title":"Differential Gene Expression and Weighted Correlation Network Dynamics in High-Throughput Datasets of Prostate Cancer","volume":"12","author":"Mohammad","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib45","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","article-title":"SOX2 in development and cancer biology","volume":"67","author":"Novak","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2024.116892_bib46","first-page":"727","article-title":"Lung adenocarcinoma resistance to therapy with EGFR\u2011tyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG","volume":"43","author":"Hu","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2024.116892_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113860","article-title":"SOX2 function in cancers: Association with growth, invasion, stemness and therapy response","volume":"156","author":"Mirzaei","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2024.116892_bib48","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1541-7786.MCR-20-0994","article-title":"Nestin is required for spindle assembly and cell cycle progression in glioblastoma cells","volume":"19","author":"Wang","year":"2021","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.biopha.2024.116892_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-018-0849-2","article-title":"Knockdown of long non-coding RNA NEAT1 inhibits glioma cell migration and invasion via modulation of SOX2 targeted by miR-132","volume":"17","author":"Zhou","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2024.116892_bib50","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s11095-008-9579-2","article-title":"Different curcuminoids inhibit T-lymphocyte proliferation independently of their radical scavenging activities","volume":"25","author":"Deters","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2024.116892_bib51","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1038\/sj.onc.1209497","article-title":"Characterization of an imatinib-sensitive subset of high-grade human glioma cultures","volume":"25","author":"H\u00e4gerstrand","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2024.116892_bib52","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/neuonc\/nor113","article-title":"Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile","volume":"13","author":"H\u00e4gerstrand","year":"2011","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib53","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/glia.23594","article-title":"Importance of GFAP isoform-specific analyses in astrocytoma","volume":"67","author":"van Bodegraven","year":"2019","journal-title":"Glia"},{"key":"10.1016\/j.biopha.2024.116892_bib54","doi-asserted-by":"crossref","first-page":"10910","DOI":"10.3390\/ijms241310910","article-title":"Unmasking the Deceptive Nature of Cancer Stem Cells: The Role of CD133 in Revealing Their Secrets","volume":"24","author":"Pospieszna","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2024.116892_bib55","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40169-018-0198-1","article-title":"The role of CD133 in cancer: a concise review","volume":"7","author":"Glumac","year":"2018","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib56","doi-asserted-by":"crossref","unstructured":"J.-J. Duan, J. Cai, L. Gao, S.-C. Yu, ALDEFLUOR activity, ALDH isoforms, and their clinical significance in cancers, J. Enzyme Inhib. Med. Chem. 38 (n.d.) 2166035. \u3008https:\/\/doi.org\/10.1080\/14756366.2023.2166035\u3009.","DOI":"10.1080\/14756366.2023.2166035"},{"key":"10.1016\/j.biopha.2024.116892_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.795762","article-title":"Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance","volume":"9","author":"Zanoni","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib58","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/neuonc\/noq070","article-title":"Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity","volume":"12","author":"Rasper","year":"2010","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.canlet.2017.12.036","article-title":"Aldehyde dehydrogenase 1A3 (ALDH1A3) is regulated by autophagy in human glioblastoma cells","volume":"417","author":"Wu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116892_bib60","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1186\/s12885-020-07153-0","article-title":"The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma","volume":"20","author":"Gan","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2024.116892_bib61","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.canlet.2012.08.021","article-title":"ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors","volume":"328","author":"Huang","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116892_bib62","doi-asserted-by":"crossref","first-page":"7122","DOI":"10.7150\/thno.35729","article-title":"Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas","volume":"9","author":"Lei","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2024.116892_bib63","first-page":"1471","article-title":"Aldehyde dehydrogenase 1A1 circumscribes high invasive glioma cells and predicts poor prognosis","volume":"5","author":"Xu","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116892_bib64","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1158\/1535-7163.MCT-18-1330","article-title":"Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM","volume":"18","author":"McKinney","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.116892_bib65","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S2213-2600(17)30378-8","article-title":"Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study","volume":"5","author":"Ahn","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.986615","article-title":"Identification and validation of SNHG gene signature to predict malignant behaviors and therapeutic responses in glioblastoma","volume":"13","author":"Fan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2024.116892_bib67","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/14656566.2020.1746269","article-title":"Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?","volume":"21","author":"Bergonzini","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.biopha.2024.116892_bib68","first-page":"231","article-title":"Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer","volume":"55","author":"Nagano","year":"2019","journal-title":"Drugs Today Barc. Spain 1998"},{"key":"10.1016\/j.biopha.2024.116892_bib69","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1158\/1535-7163.MCT-11-0730","article-title":"Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib","volume":"11","author":"Kalous","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.116892_bib70","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1038\/s41598-017-04147-0","article-title":"Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells","volume":"7","author":"Momeny","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116892_bib71","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41416-019-0496-4","article-title":"Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase","volume":"121","author":"Jathal","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116892_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2119\/molmed.2013.00108","article-title":"Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer","volume":"19","author":"Grivas","year":"2013","journal-title":"Mol. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib73","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/1535-7163.MCT-14-0736","article-title":"Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma","volume":"14","author":"Zahonero","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2024.116892_bib74","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/s41598-018-37437-2","article-title":"Genetically distinct glioma stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy","volume":"9","author":"Tanaka","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2024.116892_bib75","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116892_bib76","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.18632\/oncotarget.28010","article-title":"Multifaceted effect of chlorpromazine in cancer: implications for cancer treatment","volume":"12","author":"Kamgar-Dayhoff","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116892_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1021\/acschemneuro.8b00258","article-title":"Classics in Chemical Neuroscience: Chlorpromazine","volume":"10","author":"Boyd-Kimball","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2024.116892_bib78","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(72)92955-8","article-title":"Chlorpromazines and cancer","author":"Csatary","year":"1972","journal-title":"Lancet Lond. Engl. 2"},{"key":"10.1016\/j.biopha.2024.116892_bib79","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1600-0447.1992.tb10325.x","article-title":"Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients","volume":"85","author":"Mortensen","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.biopha.2024.116892_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1320710","article-title":"Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial","volume":"13","author":"Pace","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib81","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13046-021-02144-w","article-title":"Chlorpromazine induces cytotoxic autophagy in glioblastoma cells via endoplasmic reticulum stress and unfolded protein response","volume":"40","author":"Matteoni","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2024.116892_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.635472","article-title":"Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation In Vitro","volume":"11","author":"Matteoni","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061035","article-title":"Prognostic Relevance of Cytochrome c Oxidase in Primary Glioblastoma Multiforme","volume":"8","author":"Griguer","year":"2013","journal-title":"PLOS ONE"},{"key":"10.1016\/j.biopha.2024.116892_bib84","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2024.116892_bib85","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/der2.49","article-title":"Treating acne with the tetracycline class of antibiotics: A review","volume":"2","author":"Graber","year":"2021","journal-title":"Dermatol. Rev."},{"key":"10.1016\/j.biopha.2024.116892_bib86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.abb.2013.12.023","article-title":"Minocycline inhibits angiogenesis in vitro through the translational suppression of HIF-1\u03b1","volume":"545","author":"Jung","year":"2014","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2024.116892_bib87","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.7150\/ijbs.70708","article-title":"Minocycline binds and inhibits LYN activity to prevent STAT3-meditated metastasis of colorectal cancer","volume":"18","author":"Yang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2024.116892_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120346","article-title":"Reconnoitering the transformative journey of minocycline from an antibiotic to an antiepileptic drug","volume":"293","author":"Singh","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2024.116892_bib89","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/ene.14642","article-title":"Minocycline in neurodegenerative and psychiatric diseases: An update","volume":"28","author":"Romero-Miguel","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.biopha.2024.116892_bib90","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8659802","article-title":"Minocycline in Treating Glioblastoma Multiforme: Far beyond a Conventional Antibiotic","volume":"2020","author":"Afshari","year":"2020","journal-title":"J. Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib91","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1538-7445.AM2019-2189","article-title":"Abstract 2189: Evaluating efficacy of repurposed drugs in treatment of glioblastoma","volume":"79","author":"Neal","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116892_bib92","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s12264-010-0818-2","article-title":"Minocycline reduces astrocytic reactivation and neuroinflammation in the hippocampus of a vascular cognitive impairment rat model","volume":"26","author":"Cai","year":"2010","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.biopha.2024.116892_bib93","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/neuonc\/not073","article-title":"Inhibition of glioma growth by minocycline is mediated through endoplasmic reticulum stress-induced apoptosis and autophagic cell death","volume":"15","author":"Liu","year":"2013","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib94","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.54","article-title":"Minocycline selectively inhibits M1 polarization of microglia","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2024.116892_bib95","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/ijc.28908","article-title":"Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline","volume":"135","author":"Hu","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116892_bib96","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s00432-019-02920-4","article-title":"The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy","volume":"145","author":"Skaga","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib97","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.biopha.2024.116892_bib98","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ijc.31783","article-title":"Use of metformin and survival of patients with high-grade glioma","volume":"144","author":"Seliger","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116892_bib99","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/s41416-023-02204-2","article-title":"Is it still worth pursuing the repurposing of metformin as a cancer therapeutic?","volume":"128","author":"Lord","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2024.116892_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117717","article-title":"Anticancer mechanisms of metformin: A review of the current evidence","volume":"254","author":"Zhao","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2024.116892_bib101","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s12967-023-04263-8","article-title":"Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing","volume":"21","author":"Hua","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib102","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41574-023-00833-4","article-title":"Metformin: update on mechanisms of action and repurposing potential","volume":"19","author":"Foretz","year":"2023","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2024.116892_bib103","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.gendis.2022.12.015","article-title":"Synthetic lethal approaches to target cancers with loss of PTEN function","volume":"10","author":"Ertay","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.biopha.2024.116892_bib104","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/antibiotics12030524","article-title":"Disulfiram: Mechanisms, Applications, and Challenges","volume":"12","author":"Lanz","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.biopha.2024.116892_bib105","doi-asserted-by":"crossref","first-page":"40907","DOI":"10.18632\/oncotarget.5723","article-title":"Disulfiram inhibits TGF-\u03b2-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK\/NF-\u03baB\/Snail pathway","volume":"6","author":"Han","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116892_bib106","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022110636","article-title":"Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling","volume":"41","author":"Wang","year":"2022","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2024.116892_bib107","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2967\/jnumed.112.113324","article-title":"The Role of Copper in Disulfiram-Induced Toxicity and Radiosensitization of Cancer Cells","volume":"54","author":"Rae","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2024.116892_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.595718","article-title":"Disulfiram Chelated With Copper Inhibits the Growth of Gastric Cancer Cells by Modulating Stress Response and Wnt\/\u03b2-catenin Signaling","volume":"10","author":"Wang","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2024.116892_bib109","doi-asserted-by":"crossref","first-page":"7147","DOI":"10.1021\/acsabm.0c00949","article-title":"Combination of Disulfiram and Copper\u2013Cysteamine Nanoparticles for an Enhanced Antitumor Effect on Esophageal Cancer","volume":"3","author":"Chang","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.biopha.2024.116892_bib110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3390\/biomedicines9080852","article-title":"Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance","volume":"9","author":"Babak","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2024.116892_bib111","doi-asserted-by":"crossref","first-page":"13334","DOI":"10.1039\/C4CC04767B","article-title":"P. O\u2019Brien, On the interaction of copper( ii) with disulfiram","volume":"50","author":"Lewis","year":"2014","journal-title":"Chem. Commun."},{"key":"10.1016\/j.biopha.2024.116892_bib112","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2018.04.039","article-title":"Repurposing drugs for glioblastoma: From bench to bedside","volume":"428","author":"Basso","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2024.116892_bib113","doi-asserted-by":"crossref","first-page":"502","DOI":"10.18632\/oncotarget.969","article-title":"A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care","volume":"4","author":"Kast","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116892_bib114","doi-asserted-by":"crossref","first-page":"8052","DOI":"10.18632\/oncotarget.2408","article-title":"CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide","volume":"5","author":"Kast","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2024.116892_bib115","article-title":"A phase Ib\/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3","volume":"3","author":"Halatsch","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.biopha.2024.116892_bib116","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2024.116892_bib117","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2024.116892_bib118","first-page":"637","article-title":"The mass-action law-based new computer software, CompuSyn, for automated simulation of synergism and antagonism in drug combination studies","volume":"67","author":"Chou","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2024.116892_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100110","article-title":"Evaluation of synergism in drug combinations and reference models for future orientations in oncology","volume":"3","author":"Duarte","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.biopha.2024.116892_bib120","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","article-title":"Searching for Drug Synergy in Complex Dose\u2013Response Landscapes Using an Interaction Potency Model","volume":"13","author":"Yadav","year":"2015","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2024.116892_bib121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1006752","article-title":"Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer","volume":"15","author":"Malyutina","year":"2019","journal-title":"PLOS Comput. Biol."},{"key":"10.1016\/j.biopha.2024.116892_bib122","first-page":"263","article-title":"The Combination of Metformin and Disulfiram-Cu for Effective Radiosensitization on Glioblastoma Cells","volume":"22","author":"Rezaei","year":"2020","journal-title":"Cell J. Yakhteh"}],"updated-by":[{"DOI":"10.1016\/j.biopha.2025.118228","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000}}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332224007765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:57:02Z","timestamp":1781650622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332224007765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":122,"alternative-id":["S0753332224007765"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116892","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The combination therapy using tyrosine kinase receptors inhibitors and repurposed drugs to target patient-derived glioblastoma stem cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2024.116892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116892"}}